Insight Molecular Diagnostics Inc. (IMDX)
(Delayed Data from NSDQ)
$3.01 USD
-0.26 (-7.95%)
Updated Sep 23, 2025 04:00 PM ET
After-Market: $3.01 0.00 (0.00%) 5:40 PM ET
3-Hold of 5 3
F Value B Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
IMDX 3.01 -0.26(-7.95%)
Will IMDX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IMDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMDX
3 Medical Info Systems Stocks to Buy Amid AI Boom and Tariff Risk
IMDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for IMDX
NR7 appears for IMDX after 4.11% move
Pocket Pivot appears for IMDX after 1.19% move
Is IMDX primed for upward momentum? Upper Bollinger Band Walk shows up after gaining 1.81%
Insight Molecular Diagnostics Approves Executive Salary Increases
Is IMDX preparing to trend higher? New Uptrend shows up after slipping 3.78%